The BMP2K Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the BMP2K gene. The polyclonal format provides a heterogeneous pool of edited alleles, ensuring a robust loss-of-function model without clonal bias. These cells are suitable for investigating BMP2K-dependent processes in a cancerous background.
HeLa cells originate from a human cervical adenocarcinoma and are positive for human papillomavirus type 18 (HPV18). They exhibit aneuploidy and integrated viral oncogenes, reflecting key features of cervical carcinogenesis. The cell line’s rapid proliferation and extensively studied transcriptional and signaling profiles make it a reliable model for dissecting molecular mechanisms in cancer.
BMP2K (BMP-2-inducible kinase) is a serine/threonine kinase transcriptionally activated by BMP2 via BMPR1 and SMAD1/5/8 transcription factors. The kinase phosphorylates AP2M1 (??2 subunit of the AP-2 adaptor) at Thr156, a critical step for clathrin-mediated internalization of cell surface receptors. Through this mechanism, BMP2K modulates the trafficking and signaling output of BMP receptors and possibly other cargo. BMP2K also binds NUMB, an endocytic adaptor that participates in Notch signaling, suggesting cross-talk between BMP and Notch pathways. Representative molecular components include BMP2, BMPR1, SMAD1/5/8, AP2M1, clathrin, dynamin, and NUMB.
In HeLa cervical adenocarcinoma cells, BMP2K knockout permits investigation of how endocytic regulation impacts oncogenic signaling. Because HeLa cells harbor HPV oncoproteins that manipulate host trafficking, disrupting a kinase that controls clathrin-mediated endocytosis may reveal vulnerabilities in receptor internalization pathways relevant to cancer. Moreover, BMP2K??s role in osteoblast differentiation extends its utility to bone disorder studies, though the HeLa context primarily supports cancer-focused research. The polyclonal composition preserves genetic heterogeneity, allowing identification of consistent phenotypic changes.
Researchers can apply these polyclonal BMP2K knockout HeLa cells to study BMP pathway activity using SMAD-reporter assays, assess clathrin-mediated endocytosis via transferrin uptake, and monitor AP2M1 phosphorylation by western blotting or co-immunoprecipitation. Immunofluorescence enables visualization of AP-2 complex dynamics, while RT-qPCR quantifies downstream gene expression. The model is ideal for examining endocytic trafficking in cervical cancer, evaluating kinase-substrate relationships, and screening BMP pathway modulators. For additional information, please contact Ascent Research.
